Sfoglia per Autore
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 Monk, B; Tewari, K; Dubot, C; Caceres, M; Hasegawa, K; Shapira-Frommer, R; Salman, P; Yañez, E; Gümüş, M; Hurtado de Mendoza, M; Samouëlian, V; Castonguay, V; Arkhipov, A; Tekin, C; Li, K; Martin Nguyen, A; Monberg, M; Colombo, N; Lorusso, D
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
2023 Ray-Coquard, I; Leary, A; Pignata, S; Cropet, C; González-Martin, A; Marth, C; Nagao, S; Vergote, I; Colombo, N; Mäenpää, J; Selle, F; Sehouli, J; Lorusso, D; Alia, E; Bogner, G; Yoshida, H; Lefeuvre-Plesse, C; Buderath, P; Mosconi, A; Lortholary, A; Burges, A; Medioni, J; El-Balat, A; Rodrigues, M; Park-Simon, T; Dubot, C; Denschlag, D; You, B; Pujade-Lauraine, E; Harter, P
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
2023 Colombo, N; Gadducci, A; Sehouli, J; Rulli, E; Mäenpää, J; Sessa, C; Montes, A; Ottevanger, N; Berger, R; Vergote, I; D'Incalci, M; Churruca Galaz, C; Chekerov, R; Nyvang, G; Riniker, S; Herbertson, R; Fossati, R; Barretina-Ginesta, M; Deryal, M; Mirza, M; Biagioli, E; Iglesias, M; Funari, G; Romeo, M; Tasca, G; Pardo, B; Tognon, G; Rubio-Pérez, M; Decensi, A; De Giorgi, U; Zola, P; Benedetti Panici, P; Aglietta, M; Arcangeli, V; Zamagni, C; Bologna, A; Westermann, A; Heinzelmann-Schwarz, V; Tsibulak, I; Wimberger, P; Poveda, A
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
2023 Colombo, N; Van Gorp, T; Matulonis, U; Oaknin, A; Grisham, R; Fleming, G; Olawaiye, A; Nguyen, D; Greenstein, A; Custodio, J; Pashova, H; Tudor, I; Lorusso, D
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Matulonis, U; Lorusso, D; Oaknin, A; Pignata, S; Dean, A; Denys, H; Colombo, N; Van Gorp, T; Konner, J; Marin, M; Harter, P; Murphy, C; Wang, J; Noble, E; Esteves, B; Method, M; Coleman, R
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions
2023 Caruso, G; Tomao, F; Parma, G; Lapresa, M; Multinu, F; Palaia, I; Aletti, G; Colombo, N
Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence
2023 Plett, H; Ricciardi, E; Vacaru, V; Ramspott, J; Colombo, N; Sehouli, J; du Bois, A; Garbi, A; Richter, R; Ataseven, B; Aletti, G; Braicu, E; Heitz, F; Portuesi, R; Muallem, M; Dagres, T; Parma, G; Roser, E; Traut, A; Multinu, F; Harter, P
Myeloid neoplasms post PARP inhibitors for ovarian cancer
2023 Caruso, G; Gigli, F; Parma, G; Lapresa, M; Derio, S; Palaia, I; Colombo, N
The WID-EC test for the detection and risk prediction of endometrial cancer
2023 Barrett, J; Jones, A; Evans, I; Herzog, C; Reisel, D; Olaitan, A; Mould, T; Macdonald, N; Doufekas, K; Newton, C; Crosbie, E; Bjorge, L; Colombo, N; Dostalek, L; Costas, L; Peremiquel-Trillas, P; Ponce, J; Matias-Guiu, X; Zikan, M; Cibula, D; Wang, J; Sundstrom, K; Dillner, J; Widschwendter, M
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline ☆
2023 Sessa, C; Balmana, J; Bober, S; Cardoso, M; Colombo, N; Curigliano, G; Domchek, S; Evans, D; Fischerova, D; Harbeck, N; Kuhl, C; Lemley, B; Levy-Lahad, E; Lambertini, M; Ledermann, J; Loibl, S; Phillips, K; Paluch-Shimon, S
Endometrial carcinosarcoma
2023 Bogani, G; Ray-Coquard, I; Concin, N; Ngoi, N; Morice, P; Caruso, G; Enomoto, T; Takehara, K; Denys, H; Lorusso, D; Coleman, R; Vaughan, M; Takano, M; Provencher, D; Sagae, S; Wimberger, P; Póka, R; Segev, Y; Kim, S; Kim, J; Candido Dos Reis, F; Ramirez, P; Mariani, A; Leitao, M; Makker, V; Abu-Rustum, N; Vergote, I; Zannoni, G; Tan, D; Mccormack, M; Paolini, B; Bini, M; Raspagliesi, F; Benedetti Panici, P; Di Donato, V; Muzii, L; Colombo, N; Pignata, S; Scambia, G; Monk, B
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
2023 Disilvestro, P; Banerjee, S; Colombo, N; Scambia, G; Kim, B; Oaknin, A; Friedlander, M; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G; Gourley, C; Oza, A; González-Martín, A; Aghajanian, C; Bradley, W; Mathews, C; Liu, J; Mcnamara, J; Lowe, E; Ah-See, M; Moore, K
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
2023 Makker, V; Colombo, N; Herráez, A; Monk, B; Mackay, H; Santin, A; Miller, D; Moore, R; Baron-Hay, S; Ray-Coquard, I; Ushijima, K; Yonemori, K; Kim, Y; Guerra Alia, E; Sanli, U; Bird, S; Orlowski, R; Mckenzie, J; Okpara, C; Barresi, G; Lorusso, D
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
2023 Loverix, L; Vergote, I; Busschaert, P; Vanderstichele, A; Venken, T; Boeckx, B; Harter, P; Brems, H; Van Nieuwenhuysen, E; Pignata, S; Baert, T; Gonzalez-Martin, A; Han, S; Marth, C; Neven, P; Colombo, N; Berteloot, P; Mäenpää, J; Olbrecht, S; Laga, T; Sablon, E; Ray-Coquard, I; Pujade-Lauraine, E; Lambrechts, D; Van Gorp, T
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
2023 Schram, A; Colombo, N; Arrowsmith, E; Narayan, V; Yonemori, K; Scambia, G; Zelnak, A; Bauer, T; Jin, N; Ulahannan, S; Colleoni, M; Aftimos, P; Donoghue, M; Rosen, E; Rudneva, V; Telli, M; Domchek, S; Galsky, M; Hoyle, M; Chappey, C; Stewart, R; Blake-Haskins, J; Yap, T
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study
2023 Colombo, N; Gadducci, A; Landoni, F; Lorusso, D; Sabbatini, R; Artioli, G; Berardi, R; Ceccherini, R; Cecere, S; Cormio, G; De Angelis, C; Legge, F; Lissoni, A; Mammoliti, S; Mangili, G; Naglieri, E; Petrella, M; Ricciardi, G; Ronzino, G; Salutari, V; Sambataro, D; Savarese, A; Scandurra, G; Tasca, G; Tomao, F; Valabrega, G; Zavallone, L; Pignata, S
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
2022 Harter, P; Mouret-Reynier, M; Pignata, S; Cropet, C; Gonzalez-Martin, A; Bogner, G; Fujiwara, K; Vergote, I; Colombo, N; Nottrup, T; Floquet, A; El-Balat, A; Scambia, G; Guerra Alia, E; Fabbro, M; Schmalfeldt, B; Hardy-Bessard, A; Runnebaum, I; Pujade-Lauraine, E; Ray-Coquard, I
In memoriam: Charles Paul Morrow
2022 Maggioni, A; Biffi, R; Colombo, N
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
2022 Colombo, N; Tomao, F; Benedetti Panici, P; Nicoletto, M; Tognon, G; Bologna, A; Lissoni, A; Decensi, A; Lapresa, M; Mancari, R; Palaia, I; Tasca, G; Tettamanzi, F; Alvisi, M; Rulli, E; Poli, D; Carlucci, L; Torri, V; Fossati, R; Biagioli, E
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
2022 Vergote, I; Gonzalez-Martin, A; Ray-Coquard, I; Harter, P; Colombo, N; Pujol, P; Lorusso, D; Mirza, M; Brasiuniene, B; Madry, R; Brenton, J; Ausems, M; Buttner, R; Lambrechts, D; Ausems, M; Brenton, J; Abreu, M; Balboni, S; Banerjee, S; Barberis, M; Barretina Ginesta, M; Baurain, J; Bignami, M; Bjorge, L; Blecharz, P; Bruchim, I; Capilna, M; Cerana, N; Cicchetti, A; Collins, D; Concin, N; D'Incalci, M; Davidson, B; de la Motte Rouge, T; De Iaco, P; Demirkiran, F; Denys, H; Doerk, T; Dorum, A; Ferrero, A; Fidalgo, A; Genuardi, M; Gladieff, L; Glasspool, R; Grimm, C; Gultekin, M; Hahnen, E; Hasenburg, A; Hegmane, A; Heinzelmann, V; Hogdall, E; Janavicius, R; Jarmalaite, S; Kalachand, R; Kaneva, R; Kilickap, S; Kocian, R; Kolencik, D; Kristeleit, R; Kryzhanivska, A; Leary, A; Lemley, B; Ligtenberg, M; Lopez-Guerrero, J; Lord, C; Avall-Lundqvist, E; Maenpaa, J; Mahner, S; Marme, F; Marth, C; Mcneish, I; Merkelbach-Bruse, S; Mourits, M; Normanno, N; Oaknin, A; Ojamaa, K; Papdimitriou, C; Penault-Llorca, F; Perrone, A; Pignata, S; Pikarsky, E; Rouleau, E; Rubio, M; Sapino, A; Schmalfeldt, B; Sehouli, J; Shapira, R; Steffensen, K; Sukhin, V; Syrios, J; Szallasi, Z; Taskiran, C; Terzic, M; Tischkowitz, M; Toth, I; Van de Vijver, K; Vardar, M; Wasag, B; Wimberger, P; Witteveen, E
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile